111 related articles for article (PubMed ID: 4027992)
1. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Roberts JD; Stewart JA; McCormack JJ; Krakoff IR; Culham CA; Hartshorn JN; Newman RA; Haugh LD; Young JA
Cancer Treat Rep; 1987 Feb; 71(2):141-9. PubMed ID: 3802111
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
8. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Curt GA; Kelley JA; Fine RL; Huguenin PN; Roth JS; Batist G; Jenkins J; Collins JM
Cancer Res; 1985 Jul; 45(7):3359-63. PubMed ID: 2408749
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.
Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG
Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760
[TBL] [Abstract][Full Text] [Related]
13. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
Adamson PC; Blaney SM; Widemann BC; Kitchen B; Murphy RF; Hannah AL; Cropp GF; Patel M; Gillespie AF; Whitcomb PG; Balis FM
Cancer Chemother Pharmacol; 2004 Jun; 53(6):482-8. PubMed ID: 14999430
[TBL] [Abstract][Full Text] [Related]
14. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.
Stanton GF; Raymond V; Wittes RE; Schulman P; Budman D; Baratz R; Williams L; Petroni GR; Geller NL; Hancock C
Cancer Res; 1985 Apr; 45(4):1862-8. PubMed ID: 3978646
[TBL] [Abstract][Full Text] [Related]
15. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
